The preliminary schedule and programme of the workshop are listed below. The programme will be updated according to the feedback from the speakers, so please watch this space.
12.30 – 13.15: Registration and sandwich lunch
13.15 – 13.30: Welcome
13.30 – 17.00: Pathology, epidemiology, and genetic predisposition to testicular germ cell cancer
Daniel Berney (London, UK): What is new in the latest WHO classification of testicular tumours and what else needs to be changed.
Ariana Znaor (Lyon, France): Predicting the testicular cancer incidence burden in Europe to 2035
Jason K. Gurney (Wellington, New Zealand): Unexpected features of the epidemiology of testicular cancer among different populations in New Zealand
Katherine McGlynn (Bethesda, MD, USA): International trends in the incidence of testicular cancer: are we close to an explanation of ethnic differences?
Kate Nathanson (Philadelphia, PA, USA): Novel testicular cancer predisposition loci begin to reveal possible mechanisms.
Maria Santa Rocca (Padua, Italy): Association between copy number variations and risk of testicular cancer.
Coffee/tea break (17.00-17.30)
17.30- 19.15: Developmental pathways implicated in the pathogenesis of human germ cell malignancy
Walfred Tang (Cambridge, UK): Epigenetic dysregulation of primordial germ cells and gonocytes as a mechanism of transformation to germ cell neoplasia in situ
Anne Jørgensen (Copenhagen, DK): The involvement of NODAL/Activin pathway in testicular dysgenesis and dysregulation of pluripotency in human fetal germ cells.
Rod Mitchell (Edinburgh, UK): Deregulation of human testicular development by endocrine disruptors; evidence from experimental studies. Implications for testicular cancer in humans?
TBA Short oral presentation
Welcome reception (19.15-21.00)
09.00 – 10.30: Disruption of meiosis in pathogenesis of germ cell cancer
Ramsay J. McFarlane (Bangor, Wales, UK): Meiosis-like functions in oncogenesis
Aspasia Ploubidou (Jena, Germany): Spindle misorientation in the aetiology of germ cell disorders, hypofertility and testicular germ cell cancer.
Anne Goriely (Oxford, UK): Spermatocytic tumours: what can this rare TGCT teach us about the fundamental processes operating in the adult male germline?
Coffee/tea break (10.30-11.00)
11.00-13.00: Animal models and novel pathways implicated in the pathogenesis of germ cell cancer
Jason Heaney (Houston, TX, USA): Developmental origins and genetic risk factors of testicular germ cell tumors in mice.
Robert S. Weiss (New York, NY, USA): A mouse model of malignant testicular cancer based on KRAS activation and PTEN inactivation
Joanna Selfe (London, UK): IGF1R signalling in primordial germ cells and testicular cancer.
Trine B. Haugen (Oslo, Norway): SPRY4 and SPRY4-IT1 as possible oncogenes in TGCT
13.00-14.45: POSTER SESSION and lunch
14.45-16.30: Genomic and epigenetic changes in germ cell tumours
Hubert Schorle (Bonn, Germany): The plasticity of germ cell cancer and its dependence on the cellular microenvironment.
Leendert H. Looijenga (Rotterdam, the Netherlands): Clinical relevance of (epi)genetic changes during reprograming of GCNIS/seminoma to nonseminomas.
Louise Pyle (Philadelphia, PA, USA): Genomic changes in testicular germ cell tumors revealed by genome sequencing.
TBA: Short oral presentation
Coffee/tea break (16.30-17.00)
17.00-18.00: Immunological aspects of testicular germ cell tumours
Michal Chovanec (Bratislava, Slovakia): Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Kate Loveland (Clayton, VIC, Australia): Cytokins in testicular germ cell cancer.
9.00-10.30: Germ cell cancer risk in DSD and paediatric germ cell tumours
Leendert Looijenga (Rotterdam, the Netherlands): Risk of germ cell cancer in androgen insensitivity syndrome.
Ewa Rajpert-De Meyts (Copenhagen, Denmark): Risk of germ cell cancer in sex chromosome aneuploidy.
James Amatruda (Dallas, TX, USA): Genomics of paediatric germ cell tumours.
Lindsay Frazier (Boston, MA, USA): Should there be a different therapeutic approach to paediatric vs. adolescent/young adult germ cell tumor patients?
Coffee break (10.30-11.00)
11.00-13.00: Diagnosis of GCNIS and risk classification of overt tumours
Kristian Almstrup (Copenhagen, DK): Detection of GCNIS in semen samples – the past, the present and the future.
Klaus-Peter Dieckmann (Hamburg, Germany): Detection of GCNIS using specific miRNA profiles
Gedske Daugaard (Copenhagen, DK): Risk factors predicting relapse of stage I testicular cancer undergoing surveillance.
Joerg Beyer (Bern, Switzerland): Risk classification in patients with disseminated disease
TBA: Short oral presentation
13.00-14.00: POSTER SESSION and lunch
14.00-15.30: Management of testicular cancer resistant to treatment
Robert Hamilton (Toronto, Canada): Surgical treatment of disseminated GCTs – what is new and why?
Carsten Bokemeyer (Hamburg, Germany): Clinical features and current treatment of refractory germ cell tumours.
Christoph Oing (Hamburg, Germany): Molecular basis of treatment resistance and potential therapeutic targets.
Coffee break (15.30-16.00)
16.00-17.40: Management of late effects in testicular cancer survivors
Jourik A. Gietema (Groningen, the Netherlands): Genetic susceptibility to late effects of chemotherapy in TGCT survivors.
Mikkel Bandak (Copenhagen, DK): Testicular function in long-term survivors of testicular cancer and the effects of androgen replacement therapy.
Jakob Lauritsen (Copenhagen, DK): Risk of cardio-vascular disease in long-term survivors of testicular cancer.
Michael Kreiberg (Copenhagen, DK): Quality of life in long-term survivors of testicular cancer
17.45 Concluding remarks and closure
Conference Dinner (19.00-24.00)